← All trials
NCT05820880
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 6, 2019
- Primary completion
- Feb 23, 2022
- Completion date
- Feb 23, 2022
- First posted
- Apr 20, 2023
- Last posted
- Apr 20, 2023
- Enrollment
- 532
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ServierLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.